Increasing Approvals of Biologics Drugs to Offer an Opportunity for the Global Biologics Market

The global biologics market is estimated to grow at a CAGR of 8.6% during the forecast period. Increasing approvals of biologics drugs are offering a significant opportunity for market growth. In June 2020, EMD Serono, and Pfizer Inc. declared the approval of the US FDA supplemental Biologics License Application for BAVENCIO (avelumab). The drug is approved for the maintenance treatment of patients suffering from metastatic or locally advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy. It is the first immunotherapy that has shown a statistically potential improvement in the whole survival in the first-line setting in urothelial carcinoma. Therefore, the approval of avelumab by the US FDA is one of the potential advances for the treatment of metastatic or locally advanced urothelial carcinoma in 30 years. 

Browse the full report description of "Global Biologics Market Size, Share & Trends Analysis Report, By Product (Antibody Therapeutics, Vaccines, Cell Therapy, Gene Therapy, and Others), By Application (Cancer, Autoimmune Diseases, Infectious Diseases, and Others) and Forecast Period, 2020-2026" at https://www.omrglobal.com/industry-reports/biologics-market

Further, in October 2020, Cadila Pharmaceuticals revealed two similar biologics in the Indian market. This includes NuPTH, a teriparatide similar biologic, and Cadalimab, a similar biologic of the auto-immune treatment adalimumab. Cadila revealed four new products in India since July 2020. In August 2020, Cadila has also declared the introduction of a further similar biologic in India. The drug is sold as NuPTH, which is a similar biologic of teriparatide. This drug is a form of parathyroid hormone that is aimed for the treatment of osteoporosis by promoting bone formation. It can also be utilized in other patient groups with an enhanced risk of fracture.

Scope of the Global Biologics Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Product and Application
• Regions Covered- North America, Europe, Asia-Pacific, and Rest of the World
• Competitive Landscape- AbbVie Inc., Amgen Inc., Eli Lilly and Co., F. Hoffman-La Roche AG, and Boehringer Ingelheim GmbH

Recent Strategic Initiatives in the Global Biologics Market

• In February 2019, Alder presented a Biologics License Application (BLA) to the US FDA for eptinezumab. During 2020, Lundbeck expects to present eptinezumab for European Union approval, followed by proposals for approval in other regions across the globe including Japan and China. This acquisition will accelerate Lundbeck’s late-stage pipeline and offering access to novel capabilities in the field of monoclonal antibody treatment.
• In June 2018, Boehringer Ingelheim declared its plans to invest nearly $269.2 million into a new biological development centre (BDC) at the company’s R&D site in Biberach, Germany. The center is a major building block that encourages the company’s long-term strategy to enhance the share of pipeline’s biologicals. 

Key Questions Addressed by the Report

• What is the market growth rate?
• Which segment/region dominates the market in the base year?
• Which segment/region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected region/segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Biologics Market-Segmentation

By Product

• Antibody Therapeutics
• Vaccines
• Cell Therapy
• Gene Therapy
• Others

By Application

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Others

Global Biologics Market– Segment by Region 

North America           

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World 

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/biologics-market